Search

Your search keyword '"Naiyer Rizvi"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Naiyer Rizvi" Remove constraint Author: "Naiyer Rizvi" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
37 results on '"Naiyer Rizvi"'

Search Results

1. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

2. Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications

3. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

4. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

5. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

6. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

7. Data from Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

8. Supplementary Figure 1 from Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions

9. Supplementary Materials from Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

10. Supplementary Methods and Materials and Supplementary Figures 1-2 from Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

11. Supplementary Table 2 from Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions

12. Data from Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions

13. Supplementary Table 1 from Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions

14. Data from Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

15. Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062)

16. Abstract 3468: Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer

17. Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

18. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

19. Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer

20. Abstract CT244: A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)

21. Identifying mechanisms of acquired immune escape from sequential, paired biopsies

22. Additional file 7: of Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

23. Additional file 3: of The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

24. Additional file 3: of Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

25. Additional file 8: of Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

26. Additional file 5: of Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

27. Additional file 2: of The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

28. Phase I Study of Prolonged Infusion Bryostatin-1 in Patients

29. Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer

30. Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin

31. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer

32. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies

33. Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report

35. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.

37. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Catalog

Books, media, physical & digital resources